Psychopharmacology and Psychological Therapies

78 soru

Soru 21Soru →

A 48-year-old woman with a history of bipolar I disorder is brought to the emergency department by her husband due to progressive confusion, a coarse hand tremor, and an unsteady gait over the last three days. Her psychiatric condition has been stable on a fixed dose of lithium carbonate for the past five years. Two weeks ago, she was diagnosed with essential hypertension and started on a new antihypertensive medication by her primary care provider. On physical examination, she appears lethargic, has a coarse resting tremor in both hands, and demonstrates ataxia on finger-to-nose testing. Vital signs are within normal limits except for a blood pressure of 128/82 mmHg. Which of the following antihypertensive medications was most likely prescribed to this patient?

Cevabı ve açıklamayı göster

Cevap: Hydrochlorothiazide

Cevap

Hydrochlorothiazide
The correct answer is the medication that directly interacts with lithium clearance. The patient is exhibiting classic signs of lithium toxicity (coarse tremor, ataxia, confusion, lethargy) shortly after starting a new antihypertensive drug. Lithium is exclusively excreted by the kidneys, and its clearance is highly dependent on sodium handling in the proximal tubule. Thiazide diuretics cause mild volume depletion, which stimulates a compensatory increase in the reabsorption of both sodium and lithium in the proximal tubule. This significantly reduces lithium clearance, leading to elevated serum levels and neurologic toxicity.

Adım Adım Çözüm

1
Analyze the patient's acute presentation.
The patient exhibits progressive confusion, a coarse hand tremor, and ataxia.
Identifying the clinical syndrome is essential. These are classic neurologic signs of lithium toxicity.
2
Identify potential triggers for the acute change in the patient's condition.
The patient was recently started on a new antihypertensive medication, which correlates temporally with the onset of her toxicity symptoms.
Lithium has a narrow therapeutic index, and its levels are easily altered by concurrent medications.
3
Determine which antihypertensive classes interact with lithium.
Medications that decrease glomerular filtration rate or increase proximal tubular reabsorption (e.g., thiazide diuretics, NSAIDs, ACE inhibitors) significantly elevate serum lithium levels.
Hydrochlorothiazide is a thiazide diuretic that induces mild volume depletion, prompting the kidneys to reabsorb more sodium and lithium, precipitating toxicity.

Anahtar Kavram

Lithium is cleared by the kidneys, and its reabsorption is tied to sodium. Thiazide diuretics, ACE inhibitors, and NSAIDs decrease lithium clearance and can rapidly precipitate lithium toxicity.
Tahmini Süre:1m 15s
Soru 22Soru →

A 28-year-old man presents to the psychiatry clinic complaining of severe sadness, fatigue, and loss of interest in his usual hobbies for the past 3 weeks. He reports sleeping up to 14 hours a day and experiencing a significant decline in his appetite. Medical history is notable for an episode two years ago during which he felt "unstoppable," slept only 2 hours per night without feeling tired, and maxed out multiple credit cards on unnecessary purchases. That episode lasted for 10 days and resulted in a brief psychiatric hospitalization. Temperature is 37.0°C (98.6°F), blood pressure is 120/78 mmHg, pulse is 72/min, and respirations are 14/min. On mental status examination, the patient appears disheveled, makes poor eye contact, and exhibits psychomotor retardation. His mood is described as "miserable" and his affect is constricted. He denies suicidal ideation. Which of the following is the most appropriate initial pharmacotherapy for this patient's current symptoms?

Cevabı ve açıklamayı göster

Cevap: Quetiapine

Cevap

Quetiapine
The patient is experiencing a major depressive episode but has a distinct history of a manic episode (elevated mood, decreased need for sleep, reckless spending, and hospitalization lasting over 7 days). This presentation confirms a diagnosis of Bipolar I disorder, currently in a depressive phase. The standard of care for bipolar depression includes atypical antipsychotics such as quetiapine or lurasidone, or traditional mood stabilizers like lithium or valproate. Quetiapine is FDA-approved for bipolar depression and is the safest, most effective choice among the options provided.

Adım Adım Çözüm

1
Identify the primary underlying psychiatric disorder based on the patient's history.
The patient has a history of a 10-day episode characterized by elevated mood, decreased need for sleep, impulsivity, and hospitalization, which meets the criteria for a manic episode. This establishes a diagnosis of Bipolar I disorder.
Recognizing the underlying disorder is critical, as treating just the current symptoms without considering the full history can lead to harmful pharmacological choices.
2
Determine the current phase of the patient's illness.
The patient is currently presenting with symptoms of a major depressive episode (depressed mood, anhedonia, hypersomnia, psychomotor retardation).
Pharmacotherapy in bipolar disorder is phase-specific (e.g., acute mania vs. bipolar depression vs. maintenance).
3
Select the safest and most effective evidence-based pharmacotherapy for this specific phase.
Quetiapine is selected. Antidepressant monotherapy is strictly avoided to prevent inducing a manic episode.
Quetiapine, lurasidone, and olanzapine-fluoxetine combination are among the first-line treatments specifically approved for bipolar depression.

Anahtar Kavram

Pharmacologic Management of Bipolar Depression
Tahmini Süre:50s
Soru 23Soru →

An emergency medical team brings a 35-year-old woman to the hospital due to the acute onset of confusion, severe agitation, and muscle twitching. The patient's husband reports that she has a long-standing history of treatment-resistant depression that has been managed with phenelzine for the past year. Four days ago, she consulted a different clinician for persistent low mood and was started on an additional psychiatric medication. Her vital signs show a temperature of 39.4°C (102.9°F), pulse of 124/min, respirations of 20/min, and blood pressure of 165/95 mm Hg. Physical examination reveals profuse diaphoresis, dilated pupils, a bilateral resting tremor, and pronounced hyperreflexia with spontaneous clonus in the lower extremities. The addition of which of the following medications most likely precipitated this patient's current condition?

Cevabı ve açıklamayı göster

Cevap: Citalopram

Cevap

Citalopram
The correct answer is citalopram. This patient is experiencing serotonin syndrome, a potentially life-threatening condition characterized by the classic triad of altered mental status (confusion, agitation), autonomic instability (hyperthermia, tachycardia, diaphoresis), and neuromuscular hyperactivity (hyperreflexia, spontaneous clonus, tremor). This syndrome is most often precipitated by the concurrent use of two or more highly serotonergic medications. Phenelzine is an irreversible monoamine oxidase inhibitor (MAOI) that prevents the enzymatic breakdown of serotonin. Adding a selective serotonin reuptake inhibitor (SSRI) such as citalopram leads to a massive and rapid accumulation of synaptic serotonin, triggering this dangerous interaction. In clinical practice, MAOIs must be discontinued for at least 14 days before initiating an SSRI (and wait 5 weeks if switching from fluoxetine to an MAOI).

Adım Adım Çözüm

1
Identify the clinical syndrome based on the physical examination and vital signs.
The patient exhibits fever, tachycardia, hypertension, altered mental status, diaphoresis, and severe neuromuscular hyperactivity (hyperreflexia and spontaneous clonus), which is the classic triad of Serotonin Syndrome.
Recognizing the distinct neuromuscular signs (clonus/hyperreflexia) helps differentiate Serotonin Syndrome from Neuroleptic Malignant Syndrome (which presents with rigidity).
2
Review the patient's baseline medication list to identify predisposing factors.
The patient takes phenelzine, which is a monoamine oxidase inhibitor (MAOI) that strongly inhibits the breakdown of serotonin in the central nervous system.
MAOIs carry a severe risk of drug-drug interactions, particularly with other serotonergic agents.
3
Determine which newly added psychiatric medication could trigger this syndrome when combined with an MAOI.
Citalopram, a selective serotonin reuptake inhibitor (SSRI), blocks serotonin reuptake. Combining it with an MAOI leads to massive serotonin accumulation.
A minimum 14-day washout period is required when switching between SSRIs and MAOIs to prevent this exact complication.

Anahtar Kavram

Serotonin syndrome resulting from the combination of a monoamine oxidase inhibitor (MAOI) and a selective serotonin reuptake inhibitor (SSRI).
Soru 24Soru →

A 24-year-old woman is evaluated in the outpatient psychiatry clinic. She reports a 4-week history of severe sadness, loss of interest in her usual activities, hypersomnia, and low energy. She is diagnosed with major depressive disorder and prescribed escitalopram. The physician counsels her extensively on what to expect during the course of her treatment. Arrange the following clinical events in the typical chronological order of their occurrence after initiating this pharmacotherapy, from earliest to latest.

Öğeleri doğru sıraya koymak için sürükleyin

Cevabı ve açıklamayı göster

Cevap

The typical chronological sequence is: onset of gastrointestinal side effects (hours to days), improvement in neurovegetative symptoms like energy and sleep (1-2 weeks), improvement in subjective mood (4-6 weeks), and finally, achievement of maximal therapeutic benefit (8-12 weeks).
The timeline of selective serotonin reuptake inhibitor (SSRI) response follows a distinct and predictable sequence. Adverse effects, such as gastrointestinal upset (nausea, diarrhea) or headache, occur almost immediately (within hours to days) due to acute serotonin reuptake inhibition. The earliest therapeutic benefit is observed in neurovegetative symptoms (sleep, energy, appetite), which typically begin to improve at 1 to 2 weeks. Core affective symptoms, including depressed mood and anhedonia, take longer and typically begin to improve at 4 to 6 weeks. Finally, maximal therapeutic benefit and potential remission may require 8 to 12 weeks of continuous treatment.

Adım Adım Çözüm

1
Identify the event with the earliest onset after initiating an SSRI.
Gastrointestinal adverse effects.
These occur almost immediately (within hours to days) due to acute stimulation of serotonin receptors.
2
Identify the earliest therapeutic response.
Improvement in neurovegetative symptoms.
Sleep, appetite, and energy levels typically improve first, around weeks 1 to 2 of treatment.
3
Determine when the core mood symptoms begin to respond.
Reduction in subjective sadness.
Affective symptoms require 4 to 6 weeks to show noticeable improvement.
4
Identify the final event in the treatment timeline.
Maximum therapeutic benefit.
Full remission or maximal response often takes 8 to 12 weeks of continuous therapy.

Anahtar Kavram

Timeline of SSRI therapeutic response and side effects
Soru 25Soru →

Match each psychological therapy modality with its core clinical focus and primary indicated psychiatric condition.

Soldaki öğeye tıklayın, sonra eşleşen sağdaki öğeye tıklayın

Öğeler

Dialectical behavioral therapy
Exposure and response prevention
Motivational interviewing
Interpersonal psychotherapy

Eşleşmeler

Cevabı ve açıklamayı göster

Cevap

Dialectical behavioral therapy pairs with distress tolerance for borderline personality disorder. Exposure and response prevention pairs with graduated contact for obsessive-compulsive disorder. Motivational interviewing pairs with resolving ambivalence for substance use disorders. Interpersonal psychotherapy pairs with resolving role transitions for major depressive disorder.
Each psychological therapy has specific, evidence-based indications based on its underlying mechanism. Dialectical behavioral therapy targets the emotional dysregulation of borderline personality disorder. Exposure and response prevention breaks the cycle of obsessive-compulsive disorder. Motivational interviewing addresses the ambivalence common in substance use disorders. Interpersonal psychotherapy targets the relational stressors often underlying major depressive disorder.

Adım Adım Çözüm

1
Evaluate the clinical focus of Dialectical behavioral therapy.
Identified as focusing on mindfulness and emotional regulation for borderline personality disorder.
This matches the core curriculum developed specifically for the volatile emotional states seen in borderline personality disorder.
2
Evaluate the clinical focus of Exposure and response prevention.
Identified as involving contact with feared stimuli while withholding rituals for obsessive-compulsive disorder.
This is the definitive mechanism by which the obsessive-compulsive cycle is broken.
3
Evaluate the clinical focus of Motivational interviewing.
Identified as a client-centered approach to resolving ambivalence for substance use disorders.
Patients with addictions often struggle with readiness to change, which this therapy directly targets.
4
Evaluate the clinical focus of Interpersonal psychotherapy.
Identified as resolving role transitions and grief for major depressive disorder.
This therapy conceptualizes depressive episodes as deeply intertwined with interpersonal stressors and transitions.

Anahtar Kavram

Indications and core mechanisms of evidence-based psychological therapies.
Soru 26Soru →

A 28-year-old man with a recent diagnosis of schizophrenia is started on haloperidol. His physician is reviewing the adverse effect profile with the patient and his family. Arrange the following extrapyramidal symptoms associated with high-potency typical antipsychotics in chronological order of their characteristic onset, from earliest to latest.

Öğeleri doğru sıraya koymak için sürükleyin

Cevabı ve açıklamayı göster

Cevap

The correct sequence is: Acute dystonia, Akathisia, Pseudoparkinsonism, and Tardive dyskinesia.
The correct chronological order for the onset of extrapyramidal symptoms associated with antipsychotic medications can be remembered using the mnemonic ADAPT: Acute Dystonia (hours to days), Akathisia (days to weeks), Pseudoparkinsonism (weeks to months), and Tardive dyskinesia (months to years).

Adım Adım Çözüm

1
Identify the extrapyramidal symptom with the most rapid onset following initiation of a typical antipsychotic.
Acute dystonia appears within hours to days.
It is an acute reaction to sudden dopamine D2 receptor blockade.
2
Determine the symptom that typically follows dystonia in the expected timeline.
Akathisia generally presents within days to weeks.
It represents a subacute response to dopamine blockade and often emerges soon after or concurrently with dystonia resolution.
3
Identify the symptom that emerges in the weeks to months following treatment initiation.
Pseudoparkinsonism is the third in the sequence.
The drug-induced disruption of the nigrostriatal dopamine pathway gradually produces parkinsonian signs over weeks to months.
4
Identify the long-term complication of typical antipsychotic use.
Tardive dyskinesia is the final symptom in the sequence.
It occurs after months to years of exposure due to dopamine receptor upregulation and supersensitivity.

Anahtar Kavram

The chronological onset of extrapyramidal symptoms (EPS) due to antipsychotics typically follows the pattern: acute dystonia (hours-days), akathisia (days-weeks), pseudoparkinsonism (weeks-months), and tardive dyskinesia (months-years).
Soru 27Soru →

A 55-year-old woman is evaluated in the hospital for new-onset agitation, sweating, and tremors. She was admitted three days ago for a severe soft tissue infection and was recently transitioned to intravenous linezolid due to bacterial sensitivities. Her past medical history is significant for major depressive disorder, generalized anxiety disorder, hypertension, and hyperlipidemia. Her temperature is 38.8∘C38.8^\circ\text{C} (101.8∘F101.8^\circ\text{F}), blood pressure is 158/96 mm Hg158/96\text{ mm Hg}, and pulse is 118/min118/\text{min}. Physical examination reveals a prominently diaphoretic and agitated woman. Neurologic examination demonstrates inducible clonus in the bilateral ankles and generalized hyperreflexia. An interaction involving linezolid and which of the following home medications is the most likely cause of this patient's current symptoms?

Cevabı ve açıklamayı göster

Cevap: Paroxetine

Cevap

Paroxetine
Linezolid is an oxazolidinone antibiotic that uniquely possesses reversible, non-selective monoamine oxidase inhibitor (MAOI) activity. When linezolid is administered to a patient taking a selective serotonin reuptake inhibitor (SSRI) like paroxetine, the combination of inhibited serotonin reuptake and inhibited serotonin degradation leads to an acute, severe excess of synaptic serotonin. This manifests clinically as serotonin syndrome, characterized by the triad of autonomic instability (hyperthermia, tachycardia, diaphoresis), altered mental status (agitation), and neuromuscular hyperactivity (hyperreflexia, clonus).

Adım Adım Çözüm

1
Identify the clinical syndrome based on the patient's acute physical findings.
The patient exhibits autonomic instability (fever, tachycardia, hypertension), altered mental status (agitation), and neuromuscular hyperactivity (hyperreflexia, inducible clonus), which form the classic triad of serotonin syndrome.
Recognizing the diagnostic features of serotonin syndrome is the first step in identifying the responsible pharmacological agents.
2
Analyze the patient's recent medication changes in the context of her psychiatric history.
The patient was recently started on linezolid. Her history of major depressive disorder and generalized anxiety disorder strongly suggests she is taking a home antidepressant.
Establishing the temporal relationship between a newly administered drug and symptom onset highlights a potential adverse drug-drug interaction.
3
Determine which class of home medication interacts with linezolid to precipitate this specific syndrome.
Linezolid is an antibiotic that also functions as a reversible, non-selective monoamine oxidase inhibitor (MAOI). When combined with a selective serotonin reuptake inhibitor (SSRI) like paroxetine, it prevents serotonin breakdown while reuptake is blocked, causing massive synaptic serotonin excess.
Understanding the hidden mechanisms of action of common medications is crucial for preventing severe iatrogenic complications.

Anahtar Kavram

Serotonin syndrome can be life-threatening and is frequently precipitated by the concurrent use of a selective serotonin reuptake inhibitor (SSRI) and linezolid, an antibiotic that also possesses monoamine oxidase inhibitor (MAOI) properties.
Soru 28Soru →

Match each patient's clinical presentation with the most appropriate pharmacological treatment based on their specific comorbidities and side effect profiles.

Soldaki öğeye tıklayın, sonra eşleşen sağdaki öğeye tıklayın

Öğeler

A 24-year-old patient with major depressive disorder who is highly motivated to quit smoking and wishes to avoid medication-induced sexual dysfunction.
A 78-year-old patient with severe major depressive disorder, profound weight loss, and chronic insomnia.
A 32-year-old patient with bipolar I disorder requiring maintenance pharmacotherapy who has concurrent severe hepatic disease.
A 28-year-old patient with schizophrenia requiring antipsychotic treatment who previously developed severe galactorrhea and amenorrhea on risperidone.

Eşleşmeler

Cevabı ve açıklamayı göster

Cevap

The clinical presentations match properly to Bupropion (for smoking cessation/no sexual side effects), Mirtazapine (for insomnia/weight loss), Lithium (for hepatic disease), and Aripiprazole (to avoid hyperprolactinemia).
Each correct pairing takes into account the specific mechanism of action and side effect profile of the medication, aligning it with the patient's unique comorbidities and treatment goals.

Adım Adım Çözüm

1
Analyze the needs of the 24-year-old patient with depression.
The patient needs an antidepressant that assists with smoking cessation and lacks sexual side effects.
Bupropion uniquely fits this profile as an NDRI.
2
Evaluate the symptoms of the 78-year-old patient.
The patient has depression complicated by weight loss and insomnia.
Mirtazapine provides therapeutic benefits for all three issues due to its noradrenergic and specific serotonergic activity, plus antihistaminic effects.
3
Assess the medical comorbidities of the 32-year-old patient with bipolar disorder.
The patient has severe hepatic disease.
Lithium is renally cleared and thus safe in hepatic impairment, whereas valproate is hepatically metabolized and potentially hepatotoxic.
4
Review the previous adverse effects in the 28-year-old patient with schizophrenia.
The patient developed hyperprolactinemia on risperidone.
Aripiprazole, a D2 partial agonist, minimizes prolactin elevation and can even lower prolactin levels compared to typical agents.

Anahtar Kavram

Selection of psychotropic medications based on side effect profiles, comorbidities, and specific therapeutic benefits.
Soru 29Soru →

During morning rounds on the inpatient psychiatric unit, a medical team is evaluating a patient with schizoaffective disorder. The 34-year-old man's psychotic symptoms were previously refractory to numerous medication trials but are now well-controlled on clozapine. However, over the past week, the nursing staff reports that he has become increasingly hyperactive and irritable, pacing the halls and sleeping less than two hours per night. The team diagnoses an acute manic episode and decides to initiate an additional mood-stabilizing medication. A review of his morning laboratory results shows an absolute neutrophil count of 2,800/mm³. Which of the following medications should the team strictly avoid prescribing due to the risk of a synergistic and potentially life-threatening adverse effect?

Cevabı ve açıklamayı göster

Cevap: Carbamazepine

Cevap

The medication that must be strictly avoided is Carbamazepine.
The patient is stabilized on clozapine, an atypical antipsychotic notorious for its risk of causing severe neutropenia and agranulocytosis. Carbamazepine is a mood stabilizer and anticonvulsant that also carries a significant independent risk of bone marrow suppression, including agranulocytosis and aplastic anemia. Combining these two medications creates an unacceptable, synergistic risk of life-threatening hematologic toxicity, making their concurrent use strictly contraindicated.

Adım Adım Çözüm

1
Identify the patient's baseline medication and its primary severe adverse effect.
The patient is stabilized on clozapine, which carries a black box warning for severe neutropenia and agranulocytosis.
Recognizing baseline drug toxicities is essential before adding new pharmacological agents.
2
Evaluate the proposed mood stabilizers for overlapping toxicities.
Carbamazepine is identified as having a significant independent risk of causing bone marrow suppression and agranulocytosis.
Combining two medications with the same severe adverse effect profile creates a dangerous synergistic risk.
3
Determine the contraindicated combination.
The combination of clozapine and carbamazepine is strictly contraindicated.
The compounded risk of life-threatening agranulocytosis makes this combination unacceptably dangerous.

Anahtar Kavram

Clozapine and carbamazepine both carry a significant risk of agranulocytosis and should never be used concurrently due to the severe, synergistic risk of fatal bone marrow suppression.
Tahmini Süre:1m 0s
Soru 30Soru →

Correlate the following clinical scenarios involving psychotropic polypharmacy with their underlying pharmacokinetic or pharmacodynamic interaction mechanisms and resulting clinical consequences.

Soldaki öğeye tıklayın, sonra eşleşen sağdaki öğeye tıklayın

Öğeler

Initiation of valproate in a patient currently stabilized on lamotrigine without preemptive dose adjustment.
Addition of fluvoxamine for obsessive-compulsive symptoms in a patient stabilized on clozapine.
Concurrent administration of carbamazepine and clozapine for refractory schizoaffective disorder.
Prescribing paroxetine for comorbid anxiety in a patient maintained on a stable dose of haloperidol.
Patient initiation of over-the-counter St. John's Wort while maintained on quetiapine.

Eşleşmeler

Cevabı ve açıklamayı göster

Cevap

The clinical polypharmacy scenarios correctly map to their specific pharmacokinetic (e.g., CYP450 or UGT inhibition/induction) or pharmacodynamic mechanisms, leading to characteristic adverse outcomes.
Each psychotropic medication combination produces a highly specific and predictable pharmacokinetic or pharmacodynamic interaction. Mastering these pathways (CYP1A2, CYP2D6, CYP3A4, UGT) is essential for avoiding catastrophic iatrogenic outcomes like Stevens-Johnson syndrome, agranulocytosis, or fatal toxicities.

Adım Adım Çözüm

1
Analyze the lamotrigine and valproate interaction.
Matches with UGT inhibition leading to Stevens-Johnson syndrome.
Valproate inhibits glucuronidation (UGT), which is the sole clearance mechanism for lamotrigine.
2
Analyze the clozapine and fluvoxamine interaction.
Matches with CYP1A2 inhibition leading to seizures.
Fluvoxamine specifically targets CYP1A2, sharply elevating clozapine to toxic, epileptogenic levels.
3
Analyze the clozapine and carbamazepine interaction.
Matches with synergistic neutropenia and CYP3A4 induction.
Both drugs cause agranulocytosis. Pharmacokinetically, carbamazepine accelerates clozapine clearance.
4
Analyze the haloperidol and paroxetine interaction.
Matches with CYP2D6 inhibition leading to extrapyramidal symptoms.
Paroxetine blocks CYP2D6, slowing haloperidol metabolism and causing dose-dependent motor side effects.
5
Analyze the quetiapine and St. John's Wort interaction.
Matches with CYP3A4 induction leading to clinical destabilization.
St. John's Wort induces the CYP3A4 enzyme, stripping quetiapine from the blood and causing subtherapeutic levels.

Anahtar Kavram

Pharmacokinetic (CYP450 and UGT) and pharmacodynamic drug-drug interactions in psychopharmacology.
Soru 31Soru →

A 34-year-old male with a history of treatment-resistant schizophrenia is hospitalized for the management of severe lower extremity cellulitis. His daily psychiatric regimen includes clozapine 400 mg daily, which has successfully managed his psychotic symptoms for the past two years without major adverse effects. The patient has a 15-pack-year smoking history and typically smokes two packs of cigarettes daily. Because the hospital is a strict tobacco-free facility, he is prescribed a continuous 21-mg nicotine transdermal patch upon admission to prevent withdrawal. On hospital day 4, the nursing staff notes that the patient is profoundly sedated, confused, and experiencing excessive drooling. Later that afternoon, he suffers a witnessed generalized tonic-clonic seizure. Vital signs reveal a blood pressure of 100/60 mmHg and a heart rate of 112/min. Laboratory studies show a leukocyte count of 7,500/mm³ and a normal basic metabolic panel. Which of the following pharmacological mechanisms is the most likely primary cause of this patient's acute neurological complication?

Cevabı ve açıklamayı göster

Cevap: Loss of cytochrome P450 enzyme induction

Cevap

The most likely cause of the patient's acute presentation is the loss of cytochrome P450 enzyme induction due to smoking cessation.
The patient's presentation of a new-onset generalized tonic-clonic seizure, profound sedation, sialorrhea (excessive drooling), and hypotension is highly characteristic of acute clozapine toxicity. Clozapine is an atypical antipsychotic that is extensively metabolized by the hepatic enzyme cytochrome P450 1A2 (CYP1A2). Tobacco smoke contains polycyclic aromatic hydrocarbons (PAHs), which are potent inducers of CYP1A2. When a heavy smoker is admitted to a smoke-free hospital, the abrupt cessation of PAH exposure leads to a rapid loss of CYP1A2 induction. Consequently, the previously established home dose of clozapine is no longer metabolized at the same accelerated rate, causing its serum concentration to spike dramatically. High serum levels of clozapine are directly associated with dose-dependent toxicities, including a significantly increased risk of seizures. Importantly, while nicotine replacement therapy (such as the transdermal patch) effectively treats nicotine withdrawal cravings, it does not contain the PAHs found in combustible tobacco, meaning it cannot maintain the crucial CYP1A2 induction.

Adım Adım Çözüm

1
Analyze the patient's acute clinical presentation.
The patient developed new-onset generalized tonic-clonic seizures, profound sedation, sialorrhea (drooling), hypotension, and tachycardia.
Identifying the clinical syndrome is essential for recognizing it as acute clozapine toxicity, which has a known dose-dependent risk of seizures.
2
Review the patient's medication and environmental changes upon hospitalization.
The patient was maintained on clozapine but transitioned from heavy cigarette smoking (2 packs per day) to a nicotine transdermal patch.
Environmental and therapeutic shifts during transitions of care often trigger adverse pharmacological events.
3
Recall the pharmacokinetic relationship between smoking, clozapine, and the prescribed alternative.
Polycyclic aromatic hydrocarbons (PAHs) in tobacco smoke strongly induce CYP1A2. Nicotine replacement therapy provides nicotine but lacks PAHs, failing to maintain this induction.
Understanding the specific metabolic pathway differentiates the effects of the actual tobacco smoke from the chemical effects of nicotine.
4
Synthesize the mechanism to explain the outcome.
Abrupt cessation of PAHs leads to a rapid loss of CYP1A2 induction. The standard home dose of clozapine (a major CYP1A2 substrate) is no longer rapidly metabolized, causing serum levels to spike into the toxic range and trigger dose-dependent seizures.
This confirms that the loss of induction is the primary mechanism driving the patient's neurological complication.

Anahtar Kavram

Polycyclic aromatic hydrocarbons in tobacco smoke strongly induce cytochrome P450 1A2 (CYP1A2). Abrupt smoking cessation in a patient on a stable dose of a CYP1A2 substrate (like clozapine) causes a rapid loss of induction, leading to toxic serum drug levels. Nicotine patches do not contain hydrocarbons and will not prevent this interaction.
Soru 32Soru →

Match each patient's clinical presentation of a psychotropic medication adverse effect to the primary pharmacodynamic or pathophysiologic mechanism responsible for the finding.

Soldaki öğeye tıklayın, sonra eşleşen sağdaki öğeye tıklayın

Öğeler

A patient on maintenance therapy for bipolar I disorder presents with excessive thirst and frequent urination; urine osmolality is 150 mOsm/kg and does not increase following a water deprivation test.
A young male given an intramuscular injection for acute agitation suddenly develops a painful, sustained upward deviation of the eyes and extreme cervical muscle contraction.
A patient treated for refractory schizophrenia develops severe, socially embarrassing drooling (sialorrhea) concurrent with paradoxical complaints of blurred vision and severe constipation.
A patient receiving an augmenting agent for depression with insomnia exhibits significant daytime somnolence and a 6-kg weight gain in a month, while explicitly denying any sexual dysfunction.
A patient recently transitioned to a new long-acting injectable antipsychotic develops bilateral breast discharge, secondary amenorrhea, and early osteopenia.

Eşleşmeler

Cevabı ve açıklamayı göster

Cevap

The correct matches require linking the clinical phenotype of the adverse effect to its exact molecular neuropharmacologic mechanism, such as linking clozapine's sialorrhea to M4 agonism, and lithium's polyuria to V2 receptor adenylyl cyclase interference.
Each pair correctly links a highly specific clinical adverse effect to its precise molecular mechanism. Lithium causes nephrogenic diabetes insipidus via V2 receptor interference. High-potency typicals cause dystonia via nigrostriatal D2 blockade. Clozapine causes sialorrhea via M4 agonism despite other anticholinergic effects. Mirtazapine causes weight gain and sedation via H1 and 5-HT2C antagonism. Risperidone causes hyperprolactinemia via tuberoinfundibular D2 blockade.

Adım Adım Çözüm

1
Identify the underlying medication and clinical syndrome for each presentation.
Presentations map to Lithium (nephrogenic diabetes insipidus), High-potency typical antipsychotics (acute dystonia), Clozapine (sialorrhea/anticholinergic paradox), Mirtazapine (sedation/weight gain), and Risperidone/Paliperidone (hyperprolactinemia).
Accurate syndrome identification is required before molecular mechanisms can be mapped.
2
Correlate each identified medication/syndrome with its primary receptor binding profile or molecular target.
Lithium maps to V2/adenylyl cyclase interference; Dystonia to Nigrostriatal D2 blockade; Clozapine sialorrhea to M4 agonism; Mirtazapine to H1/5-HT2C antagonism; Hyperprolactinemia to Tuberoinfundibular D2 blockade.
USMLE Step 2 requires second- and third-order reasoning to connect clinical phenotypes directly to pharmacodynamics.

Anahtar Kavram

Pharmacodynamic mechanisms of psychotropic medication adverse effects
Tahmini Süre:2m 0s
Soru 33Soru →

An emergency department physician evaluates a 29-year-old man who presents with a rapidly spreading, painful dermatologic eruption. The patient has a known psychiatric history of bipolar I disorder, for which he has been maintained on divalproex sodium for the past four years without any manic relapses. Six weeks ago, his outpatient psychiatrist prescribed an additional medication to address a severe, functionally impairing depressive episode. Upon physical examination, the patient's temperature is 39.2°C (102.6°F). There is a widespread, tender, purpuric maculopapular rash exhibiting epidermal detachment when lateral pressure is applied. Erosions are visible on the buccal mucosa and bilateral conjunctivae. Which of the following prescribing oversights is the most likely cause of this patient's current presentation?

Cevabı ve açıklamayı göster

Cevap: Failure to halve the standard initial dosage and titration rate of the new medication

Cevap

Failure to halve the standard initial dosage and titration rate of the new medication
The patient's presentation is classic for Stevens-Johnson syndrome (SJS), a life-threatening mucocutaneous reaction characterized by fever, a purpuric maculopapular rash, mucosal erosions, and epidermal detachment (positive Nikolsky sign). The newly added medication for his bipolar depression is most likely lamotrigine. When lamotrigine is co-administered with divalproex sodium (valproate), a critical pharmacokinetic interaction occurs. Valproate is a potent inhibitor of UDP-glucuronosyltransferase (UGT), the primary enzyme responsible for lamotrigine metabolism. This inhibition effectively doubles the half-life of lamotrigine, significantly elevating its serum concentration and drastically increasing the risk of SJS. To mitigate this risk, standard psychiatric guidelines mandate that the starting dose and titration rate of lamotrigine be reduced by 50% when added to a valproate regimen. The failure to make this dosage adjustment is the oversight that precipitated this patient's condition.

Adım Adım Çözüm

1
Identify the patient's acute dermatologic complication based on the physical examination.
The patient has Stevens-Johnson syndrome (SJS), indicated by fever, a purpuric rash, mucosal erosions, and a positive Nikolsky sign (epidermal detachment with lateral pressure).
Recognizing this life-threatening drug reaction is the first step in determining which pharmacological interaction occurred.
2
Determine the most likely medication added for the patient's bipolar depression.
Lamotrigine is a first-line treatment for bipolar depression and is strongly associated with the development of SJS, especially when titrated too rapidly.
Identifying the new drug allows for the analysis of drug-drug interactions with the patient's baseline regimen.
3
Analyze the pharmacokinetic interaction between the baseline mood stabilizer (divalproex sodium) and the new agent (lamotrigine).
Divalproex sodium (valproate) is a potent inhibitor of UDP-glucuronosyltransferase (UGT), the primary enzyme responsible for metabolizing lamotrigine.
Inhibition of UGT doubles the half-life of lamotrigine, leading to rapid, toxic accumulation if standard dosing is used.
4
Identify the prescribing rule required to prevent this toxicity.
When lamotrigine is added to valproate, the initial starting dose and the subsequent titration rate of lamotrigine must be reduced by exactly 50%.
Failing to make this critical dosage adjustment is a common error that directly precipitates life-threatening cutaneous reactions.

Anahtar Kavram

Pharmacokinetic interaction between divalproex sodium (valproate) and lamotrigine via UGT inhibition, requiring a 50% dose reduction of lamotrigine to prevent Stevens-Johnson syndrome.
Tahmini Süre:2m 0s
Soru 34Soru →

A 28-year-old male with a 5-year history of schizophrenia is evaluated in the inpatient psychiatric unit for severe, persistent commanding auditory hallucinations and paranoid delusions. He is currently prescribed olanzapine 20 mg daily. His psychiatric history reveals a prior 8-week trial of risperidone 6 mg daily, which was discontinued due to a lack of efficacy. The patient insists he takes his medication every day as prescribed. The treatment team is evaluating him for treatment-resistant schizophrenia. Arrange the following management steps in the most appropriate chronological sequence for this patient.

Öğeleri doğru sıraya koymak için sürükleyin

Cevabı ve açıklamayı göster

Cevap

The optimal sequence is: 1) Verify adherence, 2) Obtain baseline ANC and complete REMS registration, 3) Initiate clozapine with slow titration, 4) Monitor ANC weekly for six months, 5) Consider ECT or augmentation for clozapine-refractory symptoms.
The correct sequence follows the standard psychiatric algorithm for suspected treatment-resistant schizophrenia (failure of two antipsychotics). Adherence must be verified first to rule out pseudo-resistance. Once true resistance is established, clozapine is the drug of choice. Due to the risk of life-threatening agranulocytosis, baseline ANC and REMS registration must precede initiation. Clozapine is then started with a slow dose titration, followed by mandatory weekly ANC monitoring for the first six months. If clozapine fails, ECT or augmentation (clozapine-refractory management) is the final step.

Adım Adım Çözüm

1
Rule out pseudo-resistance.
Medication adherence is objectively verified.
Non-adherence is the most common cause of apparent treatment failure in schizophrenia. It must be ruled out before escalating to clozapine.
2
Prepare for clozapine initiation.
Baseline ANC is obtained and REMS registration is completed.
Clozapine carries a black-box warning for severe neutropenia; baseline labs and federal REMS registry enrollment are prerequisites for prescription.
3
Start clozapine pharmacotherapy.
Clozapine is initiated and titrated slowly.
A slow titration schedule is required to mitigate the risk of adverse cardiovascular events and dose-dependent seizures.
4
Maintain clozapine safety monitoring protocols.
Weekly ANC monitoring is conducted for 6 months.
REMS protocol mandates weekly blood draws for the first 6 months to detect agranulocytosis early and ensure patient safety.
5
Address clozapine-resistant schizophrenia.
ECT or augmentation strategies are considered.
If a patient fails clozapine monotherapy, they are considered clozapine-refractory, and more invasive or combinatory treatments are warranted.

Anahtar Kavram

Algorithm for Treatment-Resistant Schizophrenia
Tahmini Süre:1m 30s
Soru 35Soru →

A young adult male is brought to the inpatient psychiatric unit by his family due to a profound decline in functioning over the past two weeks. The patient has been entirely mute, persistently holds his arms in rigid, unnatural postures for hours, and refuses all oral intake. His current daily medication regimen includes risperidone and fluoxetine. Vital signs show a heart rate of 105/min105/\text{min} and blood pressure of 130/85 mm Hg130/85\text{ mm Hg}; he is afebrile. The psychiatry team suspects catatonia. Arrange the following management steps in the most appropriate sequential order for evaluating and treating this patient's current condition.

Öğeleri doğru sıraya koymak için sürükleyin

Cevabı ve açıklamayı göster

Cevap

The correct sequential order for managing catatonia is to first discontinue the offending antipsychotic, then perform a lorazepam challenge test, followed by initiating scheduled lorazepam therapy, and finally reserving electroconvulsive therapy for refractory cases.
The standard of care for treating catatonia requires a stepwise approach to maximize safety and efficacy. The absolute first step is the cessation of dopamine-blocking agents (such as risperidone), as these can worsen the catatonic state and provoke neuroleptic malignant syndrome. Once the offending agent is removed, the diagnosis is confirmed and initially treated with a lorazepam challenge. If the patient responds, they are placed on scheduled lorazepam to maintain the therapeutic effect. Electroconvulsive therapy (ECT) is generally reserved as a last-line treatment for medication-refractory catatonia, unless the patient is actively deteriorating with malignant catatonia (fever, autonomic instability), in which case it is used earlier.

Adım Adım Çözüm

1
Identify the diagnosis of catatonia and stop offending agents.
Risperidone is discontinued.
Dopamine antagonists like risperidone can precipitate or worsen catatonia and cross over into neuroleptic malignant syndrome.
2
Perform a diagnostic challenge.
An intravenous lorazepam challenge is administered.
This confirms the diagnosis, as most patients with catatonia will show rapid, albeit temporary, improvement following a dose of intravenous benzodiazepines.
3
Establish a maintenance treatment plan.
Scheduled, high-dose lorazepam is initiated.
Once responsiveness to benzodiazepines is established, standing doses are required to prevent relapse of catatonic symptoms while treating the underlying psychiatric illness.
4
Determine the next step if pharmacological treatment fails.
Electroconvulsive therapy (ECT) is considered.
ECT is highly efficacious but invasive, so it is strictly reserved for patients who do not respond to scheduled benzodiazepines, or those who present with malignant catatonia (severe autonomic instability).

Anahtar Kavram

Stepwise management of catatonia
Soru 36Soru →

A 62-year-old retired architect with a long-standing history of bipolar I disorder is evaluated in the emergency department for worsening confusion, sluggishness, and an unsteady gait over the past three days. He has been psychiatrically stable on a fixed dose of lithium carbonate for eight years without any recent dosage adjustments. His husband reports that the patient recently started taking an over-the-counter analgesic multiple times a day for a severe flare-up of knee osteoarthritis. Vital signs are within normal limits. Physical examination reveals a coarse, irregular tremor in both upper extremities and pronounced dysarthria. The patient is unable to perform tandem walking without losing his balance. Which of the following mechanisms best explains how the newly initiated analgesic precipitated this patient's current symptoms?

Cevabı ve açıklamayı göster

Cevap: Decreased renal clearance secondary to afferent arteriole vasoconstriction

Cevap

The over-the-counter medication (an NSAID) precipitated toxicity via decreased renal clearance secondary to afferent arteriole vasoconstriction.
The correct answer accurately describes the mechanism of NSAID-induced lithium toxicity. This patient is presenting with classic symptoms of lithium toxicity (coarse tremor, ataxia, dysarthria, and altered mental status). His recent initiation of an over-the-counter analgesic for osteoarthritis points strongly to a nonsteroidal anti-inflammatory drug (NSAID). NSAIDs inhibit cyclooxygenase (COX), leading to decreased synthesis of prostaglandins. In the kidney, prostaglandins are responsible for maintaining vasodilation of the afferent arteriole. Loss of this dilatory effect results in afferent arteriole vasoconstriction, a decreased glomerular filtration rate (GFR), and subsequently decreased renal clearance of lithium. Because lithium has a very narrow therapeutic index, this reduction in clearance rapidly leads to toxic serum levels.

Adım Adım Çözüm

1
Diagnose the patient's acute clinical presentation based on symptoms and medication history.
The patient is experiencing acute lithium toxicity, characterized by confusion, coarse tremors, ataxia, and dysarthria in the setting of chronic lithium use.
Lithium has a narrow therapeutic index, and its neurological toxicities classically include coarse tremor, cerebellar dysfunction (ataxia, dysarthria), and altered mental status.
2
Identify the likely over-the-counter medication taken for the patient's osteoarthritis.
The patient is most likely taking a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen or naproxen.
NSAIDs are standard, widely available over-the-counter first-line analgesics for osteoarthritis flare-ups.
3
Determine the pharmacological mechanism by which NSAIDs interact with lithium.
NSAIDs inhibit cyclooxygenase (COX), reducing renal prostaglandins. This causes afferent arteriole vasoconstriction, dropping the glomerular filtration rate (GFR) and decreasing the renal clearance of lithium.
Lithium is filtered exclusively by the kidneys. Any drug that reduces GFR (NSAIDs) or increases proximal tubular reabsorption (thiazides, ACE inhibitors) will lead to toxic accumulation of lithium.

Anahtar Kavram

Lithium relies entirely on renal clearance. Medications that decrease glomerular filtration rate, such as NSAIDs (via afferent arteriole vasoconstriction), can precipitate dangerous lithium toxicity.
Soru 37Soru →

A 45-year-old woman is evaluated on the medical ward by the psychiatric consultation-liaison service due to acute-onset agitation and confusion. The patient has a history of major depressive disorder, which has been well controlled on sertraline 150 mg daily for the past two years, and poorly controlled type 2 diabetes mellitus. She was admitted three days ago for a severe diabetic foot infection. Deep tissue cultures grew Vancomycin-resistant Enterococcus faecium (VRE). Yesterday, her intravenous antibiotics were discontinued, and she was transitioned to a targeted oral antibiotic therapy to facilitate hospital discharge. This morning, she became rapidly disoriented and restless. Temperature is 38.6°C (101.5°F), blood pressure is 165/95 mm Hg, pulse is 128/min, and respirations are 20/min. Physical examination reveals a diaphoretic, flushed woman who is unable to answer questions coherently. Her pupils are dilated (6 mm bilaterally). Neurologic examination is notable for 4+ deep tendon reflexes in the lower extremities, spontaneous myoclonus, and sustained bilateral ankle clonus. Which of the following pharmacologic actions of the newly initiated antibiotic is most directly responsible for this patient's current clinical state?

Cevabı ve açıklamayı göster

Cevap: Inhibition of monoamine oxidase

Cevap

Inhibition of monoamine oxidase
This patient's presentation of altered mental status, autonomic instability (fever, tachycardia, hypertension, diaphoresis), and profound neuromuscular hyperactivity (myoclonus, hyperreflexia, sustained clonus) represents the classic triad of serotonin syndrome. The patient was already taking sertraline, a selective serotonin reuptake inhibitor (SSRI). The abrupt onset of symptoms followed the initiation of a targeted oral antibiotic for Vancomycin-resistant Enterococcus (VRE). Linezolid is an oxazolidinone antibiotic frequently used for VRE and methicillin-resistant Staphylococcus aureus (MRSA) infections. A critical pharmacological characteristic of linezolid is its structural similarity to monoamine oxidase inhibitors (MAOIs), which gives it weak, reversible, nonselective MAOI activity. When administered with an SSRI, linezolid inhibits the enzymatic degradation of serotonin while the SSRI inhibits its reuptake. This leads to a massive accumulation of synaptic serotonin and precipitates serotonin syndrome. Concurrent use of linezolid and serotonergic antidepressants is contraindicated.

Adım Adım Çözüm

1
Identify the patient's acute toxidrome from the clinical presentation.
The patient has altered mental status, autonomic instability (fever, tachycardia, hypertension, diaphoresis), and neuromuscular hyperactivity (hyperreflexia, myoclonus, clonus).
This triad is the classic clinical presentation of serotonin syndrome.
2
Determine the inciting pharmacological trigger.
The patient was stable on sertraline (an SSRI) and developed the syndrome shortly after starting a new oral antibiotic for VRE.
Linezolid is a primary oral treatment option for VRE infections and is known to cause severe drug interactions.
3
Identify the mechanism by which the antibiotic caused this syndrome.
Linezolid possesses weak, reversible nonselective monoamine oxidase inhibitor (MAOI) activity.
Combining an MAOI (linezolid) with an SSRI (sertraline) prevents the breakdown and reuptake of serotonin, leading to a massive accumulation of serotonin in the central nervous system, precipitating serotonin syndrome.

Anahtar Kavram

Linezolid has off-target monoamine oxidase inhibitor (MAOI) properties and can precipitate life-threatening serotonin syndrome when co-administered with serotonergic agents like SSRIs.
Tahmini Süre:2m 0s
Soru 38Soru →

A 34-year-old female with schizoaffective disorder is admitted to the hospital for intravenous antibiotic therapy for a complicated cellulitis. Her psychiatric symptoms have been well controlled for the past three years on a stable dose of clozapine. She typically smokes one and a half packs of cigarettes daily but is currently in a strict smoke-free inpatient unit; a transdermal nicotine patch was prescribed on admission to prevent withdrawal. Her other home medications include a combined oral contraceptive pill and ibuprofen as needed. On hospital day 4, the patient becomes progressively lethargic and develops significant sialorrhea. Later that evening, she experiences a generalized tonic-clonic seizure. Her vital signs are temperature 37.1°C (98.8°F), blood pressure 110/70 mm Hg, pulse 92/min, and respirations 14/min. Laboratory studies show a normal basic metabolic panel, and her white blood cell count is 8,500/mm³. Which of the following is the most likely pharmacological explanation for this patient's acute neurological presentation?

Cevabı ve açıklamayı göster

Cevap: Decreased hepatic drug clearance due to the removal of a cytochrome P450 inducer

Cevap

The correct underlying mechanism is decreased hepatic drug clearance due to the removal of a cytochrome P450 inducer.
The correct answer describes decreased hepatic drug clearance due to the removal of a cytochrome P450 inducer. This patient is exhibiting textbook signs of clozapine toxicity, which classically presents with severe sedation (lethargy), sialorrhea (excessive drooling), and dose-dependent generalized tonic-clonic seizures. Clozapine is primarily metabolized by the cytochrome P450 1A2 (CYP1A2) hepatic enzyme. Tobacco smoke contains polycyclic aromatic hydrocarbons (PAHs), which are potent inducers of CYP1A2. When a heavy smoker is abruptly placed in a smoke-free environment (such as an inpatient hospital admission), the induction of CYP1A2 rapidly diminishes. This leads to a significant decrease in the clearance of clozapine, causing serum levels to rise precipitously into toxic ranges, even though the prescribed medication dose remained unchanged.

Adım Adım Çözüm

1
Analyze the patient's acute symptoms.
The patient exhibits lethargy, sialorrhea (excessive drooling), and a generalized tonic-clonic seizure.
Identifying the clinical toxidrome is the first step to pinpointing the offending agent.
2
Correlate the toxidrome with the patient's medication list.
The symptoms represent classic dose-dependent toxicities of clozapine.
Clozapine side effects include severe sedation, prominent sialorrhea, and a dose-dependent reduction in the seizure threshold.
3
Identify the trigger for the sudden onset of toxicity in a previously stable patient.
The patient is a heavy smoker who was abruptly forced to cease smoking upon hospital admission.
Changes in environmental exposures, particularly smoking, can drastically alter the metabolism of psychiatric medications.
4
Determine the pharmacokinetic mechanism connecting smoking cessation to clozapine levels.
Tobacco smoke contains polycyclic aromatic hydrocarbons (PAHs) that strongly induce CYP1A2, the primary enzyme that metabolizes clozapine.
Abrupt smoking cessation leads to a rapid loss of CYP1A2 induction, causing clozapine metabolism to slow down and serum levels to spike, precipitating toxicity despite an unchanged oral dose.

Anahtar Kavram

Polycyclic aromatic hydrocarbons in tobacco smoke strongly induce CYP1A2. Abrupt smoking cessation in patients taking CYP1A2 substrates like clozapine leads to decreased clearance, elevated serum levels, and potentially life-threatening dose-dependent toxicity.
Soru 39Soru →

A 32-year-old woman with a history of severe, treatment-resistant major depressive disorder is evaluated in the psychiatry clinic. She has experienced minimal clinical improvement on an optimized dose of fluoxetine over the past 12 weeks. The psychiatrist decides to discontinue fluoxetine and initiate phenelzine. To prevent life-threatening complications such as serotonin syndrome and hypertensive crisis, strict guidelines must be followed during this transition and in the event of future medication changes. Arrange the following clinical management steps in the correct chronological sequence required to safely execute this treatment plan.

Öğeleri doğru sıraya koymak için sürükleyin

Cevabı ve açıklamayı göster

Cevap

The correct chronological sequence is to first discontinue fluoxetine, then observe a 5-week washout period, followed by initiating phenelzine with a tyramine-restricted diet, and finally maintaining those restrictions for 2 weeks if phenelzine is ever discontinued.
The sequence correctly accounts for the pharmacokinetic and pharmacodynamic properties of fluoxetine and phenelzine. Fluoxetine must be stopped first, followed by a mandatory 5-week washout due to the long half-life of its active metabolite norfluoxetine. Only then can phenelzine and a low-tyramine diet be initiated. If phenelzine is later stopped, its irreversible MAO inhibition requires restrictions to continue for 2 weeks while the body synthesizes new enzymes.

Adım Adım Çözüm

1
Discontinue the administration of fluoxetine.
Blood levels of fluoxetine and its active metabolites begin to slowly decline.
Concomitant use of SSRIs and MAOIs is absolutely contraindicated due to the high risk of fatal serotonin syndrome.
2
Maintain a strict 5-week medication-free washout period.
Sufficient clearance of the SSRI from the patient's system is achieved.
Fluoxetine has a uniquely long half-life (up to 7-15 days for norfluoxetine), necessitating a 5-week washout rather than the standard 2-week washout required for most other SSRIs.
3
Initiate phenelzine therapy while concurrently starting a low-tyramine diet.
Irreversible inhibition of monoamine oxidase begins safely without excess systemic serotonin or tyramine.
Once the SSRI is cleared, the MAOI can be started. The tyramine-restricted diet is necessary to prevent a sympathomimetic hypertensive crisis.
4
Maintain the low-tyramine diet and avoid serotonergic agents for 2 weeks if phenelzine is ever discontinued.
The patient remains safe from drug-food and drug-drug interactions until native enzyme function is restored.
Irreversible MAOIs permanently deactivate existing MAO enzymes. It takes the body approximately 2 weeks to synthesize new MAO enzymes after the drug is stopped.

Anahtar Kavram

Cross-tapering protocols between serotonergic agents and MAOIs require specific washout periods to prevent serotonin syndrome: 5 weeks after stopping fluoxetine, and 2 weeks after stopping an MAOI.
Tahmini Süre:1m 30s
Soru 40Soru →

A 29-year-old man is brought to the emergency department by his partner due to a rapidly spreading rash and fever. Over the past 48 hours, he developed flu-like symptoms followed by painful, erythematous macules on his chest and back. Physical examination reveals a temperature of 39.2°C (102.6°F). The macules have coalesced into large areas of blistering, and the epidermis sloughs off with gentle lateral pressure. Ulcerations are visible on his buccal mucosa and vermilion border. The patient has a 4-year history of bipolar I disorder and has been maintained on divalproex sodium. Three weeks ago, he sought treatment for a severe depressive episode, and his psychiatrist added a second medication to his regimen. The new medication was prescribed at a starting dose of 25 mg daily. Which of the following pharmacokinetic or pharmacodynamic mechanisms best explains the pathogenesis of this patient's current dermatologic emergency?

Cevabı ve açıklamayı göster

Cevap: Inhibition of hepatic glucuronidation by the maintenance mood stabilizer

Cevap

Inhibition of hepatic glucuronidation by the maintenance mood stabilizer
The correct answer is inhibition of hepatic glucuronidation by the maintenance mood stabilizer. The patient is presenting with Stevens-Johnson syndrome (SJS) or Toxic Epidermal Necrolysis (TEN), a life-threatening mucocutaneous reaction characterized by a blistering rash, mucosal ulcerations, and a positive Nikolsky sign. In the context of bipolar disorder, the most likely medication added for a depressive episode that causes SJS is lamotrigine. Lamotrigine is metabolized in the liver primarily by UDP-glucuronosyltransferase (UGT). The patient's maintenance medication, divalproex sodium (valproic acid), is a potent inhibitor of UGT. When lamotrigine is added to a valproate regimen without appropriate dose adjustments, its clearance is halved, leading to a rapid and dangerous increase in plasma lamotrigine levels. This significantly elevates the risk of SJS/TEN. Therefore, when initiating lamotrigine in a patient taking valproate, the starting dose must be reduced by 50% (typically 25 mg every other day) and titrated much more slowly.

Adım Adım Çözüm

1
Identify the acute clinical syndrome based on the physical examination findings.
The patient has fever, a blistering rash with a positive Nikolsky sign (epidermal sloughing), and mucosal ulcerations, which is highly characteristic of Stevens-Johnson syndrome (SJS) or Toxic Epidermal Necrolysis (TEN).
Recognizing this dermatologic emergency is critical to identifying the offending pharmacological trigger.
2
Determine the most likely offending psychotropic medication added to the patient's regimen.
The patient was prescribed a medication for bipolar depression starting at 25 mg daily. Lamotrigine is a first-line treatment for bipolar depression and is known to carry a black box warning for SJS/TEN.
Connecting the psychiatric indication (bipolar depression) and the typical starting dose (25 mg) points directly to lamotrigine.
3
Analyze the pharmacokinetic interaction between the maintenance therapy and the newly added agent.
The patient was already on divalproex sodium (valproic acid). Valproic acid is a potent inhibitor of UDP-glucuronosyltransferase (UGT), the primary enzyme responsible for metabolizing lamotrigine.
Understanding drug metabolism is required to explain why standard dosing led to a toxic outcome in this specific patient.
4
Apply the interaction mechanism to the dosing error.
Because valproic acid inhibits UGT, it significantly decreases lamotrigine clearance. The standard starting dose of 25 mg daily is therefore too high in this context and leads to toxic lamotrigine levels, precipitating SJS/TEN. The dose should have been reduced by 50% (to 25 mg every other day).
This confirms that the inhibition of hepatic glucuronidation by the maintenance medication is the correct mechanism for the toxicity.

Anahtar Kavram

Valproic acid inhibits UDP-glucuronosyltransferase (UGT), which doubles the plasma concentration of concurrently administered lamotrigine. To mitigate the severe risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), the starting dose of lamotrigine must be reduced by 50% when a patient is taking valproic acid.
ÖncekiSayfa 2 / 4Sonraki
Psychopharmacology and Psychological Therapies Alıştırma Soruları — USMLE Step 2 CK — Sayfa 2 | Examkin